Purpose: To describe the collaborative framework used by National Institute of Nursing Research (NINR) investigators to advance symptom science and to provide a research exemplar. Model: The National Institutes of Health (NIH) Symptom Science Model (SSM) was developed to guide symptom science researchers to understand the molecular underpinnings of symptoms using innovative "omics" approaches. The process begins with a review of the literature to understand the state of the science of the symptoms of interest and is followed by cross-sectional, case-controlled, or longitudinal studies to identify potential biological correlates of these symptoms. The final steps include validation of these potential symptom biomarkers using multidisciplinary, collaborative, preclinical experiments, and proof-of-concept clinical trials. Research Exemplar: Using the NIH SSM as a guide, the identification of biologic correlates of symptoms using omics and bioinformatic strategies depends on determining the distinct phenotype of the symptoms of interest. The identified biologic correlates of these symptoms are then validated for their functional relevance using in vitro and ex vivo experiments, or through proof-of-concept clinical trials. NINR investigators observed that activation of specific receptors in neural networks can trigger inflammation-related fatigue development and predispose patients to develop chronicity of symptoms. Specifically targeting these neural receptors can reduce symptom intensity. Conclusions: Through using the NIH SSM as a guide, NINR investigators quickly generate data and discoveries that significantly advance symptom science by simultaneously collaborating with multiple experts and core laboratories to identify more correlates and validate their functional relevance in order to further understand the biological underpinnings of the symptoms of interest. Clinical Relevance: The collaborative framework used by NINR investigators as guided by the NIH SSM identifies functionally relevant clinical markers that can explain the biological underpinnings of symptoms and can be targeted to optimize symptom management.
multidisciplinary collaboration that advances symptom science related to fatigue.
One of the themes driving the strategic plan of the NINR is symptom science. The "hallmark of nursing practice is symptom assessment and management, with the goal of exposing triggers, reducing severity, and limiting impact" (Corwin et al., 2014, p. 346) . A symptom has been described as a self-reported perception of an individual's experience of disease or physical disturbance (Dodd et al., 2001 ) and can include an experience such as fatigue, pain, or cognitive dysfunction. Clustering of symptoms occurs when patients experience multiple related symptoms concurrently (Xiao, 2010) . Symptoms are of clinical, research, and policy concern because they are the most common reason that patients seek health care (Rutledge & McGuire, 2004) . The NINR intramural research program is dedicated to conducting basic and clinical research on the interactions among molecular mechanisms underlying a single symptom or cluster of symptoms and environmental influences on individual health outcomes.
Scientists at the NINR intramural research program collaborate in a team science approach primarily using shared resources, which provide flexibility and agility to adapt to the dynamic nature of symptoms biology. Considering that common biologic mechanisms are proposed to underpin symptoms (e.g., inflammation, mitochondrial dysfunction), the NINR laboratory created core sections (e.g., genomics, proteomics, in vitro experiments) allowing NINR investigators to share resources to identify specific biologic correlates of the symptoms of interest. In addition, NINR intramural scientists work collaboratively with a variety of laboratories and clinical teams from other institutes and centers on the NIH campus, in Bethesda, Maryland, that are established through linkages and long-term commitments to address specific research questions.
Symptom Science Model
To align with the NIH initiative to expand bedsideto-bench-to-bedside research activities across disciplines, investigators at the NINR intramural research program developed the NIH SSM to describe an investigative sequence for symptom science research (Cashion & Grady, 2015) . The NIH SSM addresses the recent call to adapt the bedside-to-bench model in nursing research to focus on the process and outcomes that have direct bearing on improving care provided to patients, which is consistent with models of nursing theory and the nursing process (Cowman, 2018) . Hence, the NIH SSM proposes that translational research in symptom science should proceed in the following systematic step-by-step process: (a) identification of a symptom or symptom cluster, (b) characterization of the phenotype of this symptom or symptom cluster, (c) use of the phenotypic characterization to identify potential biomarkers using hypothesis-generating "omic" methods as recommended by the genomic nursing science blueprint (Genomic Nursing State of the Science Advisory Panel et al., 2013) , and (d) validation of these identified biomarkers using proof-of-concept clinical trials or preclinical experiments. The NIH SSM advances nursing science by providing practical guidance on how to better translate new knowledge and discoveries to clinically relevant applications.
The NIH SSM has been utilized widely. In the NINR, it has been used to help unravel the biologic underpinnings of complex gastrointestinal symptoms, to delineate the physiological mechanisms that can explain the co-occurrence of symptoms reported by military personnel returning from deployment, and to identify therapeutic targets for cancer-related fatigue (Cashion, Gill, Hawes, Henderson, & Saligan, 2016; Fourie et al., 2014; Gill et al., 2015) . NINR investigators focus on understanding the trajectory and causes of symptoms. They also seek to understand associations and biological underpinnings of the co-occurrence of symptoms with the goal of identifying distinct and shared functional pathways that can be used as potential therapeutic targets to reduce the debilitating effects of symptoms. A specific example of how the NIH SSM can serve as a guide for research activities of investigators within the NINR intramural research program follows.
Research Exemplar Symptom of Interest-Fatigue
Fatigue is a multidimensional symptom that impacts 38% of community-based individuals and 42% of primary care patients (Ricci, Chee, Lorandeau, & Berger, 2007; Sharpe & Wilks, 2002) . It is one of the most common and most debilitating symptoms in cancer, especially during treatment . It has significant repercussions on both direct and indirect health economic outcomes (Carlotto, Hoqsett, Maiorini, Razulis, & Sonis, 2013) , costing an estimated annual lost productive time of US$330 million mostly due to reduced work performance (Ricci et al., 2007) . In cancer, fatigue had the greatest negative impact on daily activity, physical well-being/function, and relationships with significant others (Hofman, Ryan, Figueroa-Moseley, Jean-Pierre, & Morrow, 2007) .
Cancer-related fatigue is described as a persistent, subjective sense of tiredness that interferes with usual functioning (Patrick et al., 2003) . It can be distinguished from normal everyday tiredness, because it is more frequent, unrelenting, unpredictable, and unresolved by rest (Dittner, Wessely, & Brown, 2004; Hewlett et al., 2005) . The fatigue experience may be influenced by a combination of physiological factors (e.g., inflammation or central nervous system dysfunction), psychosocial factors (e.g., depressed mood or anxiety), and lifestyle factors (e.g., diet, exercise, alcohol use, tobacco use, or social role; Bower, 2012; Chaudhuri & Behan, 2000; Fritschi & Quinn, 2010; Lasselin et al., 2012; Zwarts, Bleijenberg, & van Engelen, 2008) . Fatigue also co-occurs with other symptoms (e.g., pain, depression) contributing to symptom burden, which negatively affects health-related quality of life of patients (Shi et al., 2011) .
The etiology of fatigue is unknown, but it is believed to have central and peripheral components. Central fatigue is hypothesized to result from a decrease in central nervous system drive brought about by serotonergic pathways limiting muscle fiber recruitment during exertion, reducing muscle glycolysis, oxygen consumption, and cardiovascular function (Kay et al., 2001; Noakes, Peltonen, & Rusko, 2001 ). Peripheral fatigue is the inability of a particular muscle to perform a task even with an increased neural drive. This is thought to be caused by an action potential failure, cross-bridge formation impairment, or excitation contraction coupling failure amidst increased neural stimulation (Kay, St. Clair, Mitchell, Lambert, & Noakes, 2000) . The interplay between central and peripheral types of fatigue remains unclear, although an increasing body of literature has indicated a potential interaction of both mechanisms (Girard, Lattier, Maffiuletti, Micallef, & Millet, 2008; Struder, Hollmann, Duperly, & Weber, 1995) . The NIH SSM advances nursing science, especially in fatigue research, by providing a clear guide to improve our understanding of the biological underpinnings of fatigue, which is a complex construct with several phenotypes. The model will pave the way for the development of optimal management for this distressing symptom.
Review of the Literature
To understand the state of the science of biomarker discovery in the field of cancer-related fatigue (CRF), an exhaustive review of the literature was necessary to identify the gaps in the field and provide research direction for the team. The author was tasked to lead the Multinational Association of Supportive Care in Cancer (MASCC) Fatigue Study Group, specifically the Biomarker Working Group. This multidisciplinary study group is composed of professionals from different disciplines and specialties from more than 70 countries and was created to promote collaboration among researchers and clinicians to understand the causes, definition, and measurement of CRF. The expertise from this study group served as a great resource for the first task of the NIH SSM, which was to characterize the fatigue phenotype. So, the author conducted a systematic review with the members of the MASCC Fatigue Study Group to understand the biology of CRF . The group reviewed 47 articles, of which 25 were cross-sectional and 22 were longitudinal in design. The review illustrated the complexity of studying CRF and possible biomarkers involved in its etiology. Although the review did not find a validated marker of CRF, it revealed that the majority of reviewed articles investigated the association of CRF with immune response and inflammation. The review concluded that the development and persistence of CRF are influenced mostly by immune dysregulation and inflammation. Other biologic processes that were found to play a role in the CRF experience included metabolic, neuroendocrine, hypothalamic-pituitary-adrenal axis, and genetics.
Similarly, another review was conducted by the author and his colleagues, who are former trainees at one of the NINR intramural training programs (i.e., postdoctoral fellow, Graduate Partnership Program, the Summer Genetics Institute, or the NINR Methodologies Boot Camp) and are now early career faculty members of various nursing schools in the United States. This second review investigated the biological basis of clustering of cancer-related symptoms and identified that biomarkers related to inflammation (e.g., cytokines) were the most studied and also the ones that showed the most significant relationships with clusters of cancerrelated symptoms. Similar to the findings of the MASCC team review, the findings of this review suggested that clustering of symptoms related to cancer or cancer therapy were linked to immune and inflammatory pathways (Lynch Kelly et al., 2016) . Other reviews were conducted by the author and his mentees who had fatigue-related research topics. One review found that mitochondrial dysfunction was associated with reports of fatigue across medical conditions (Filler et al., 2014) . Another review observed that behavioral markers such as high catastrophizing were associated with fatigue severity (Lukkahatai & Saligan, 2013) . The findings from these reviews guided the research directions of the study team and informed the team of outcomes to include and specific methodologies to incorporate in follow-up studies.
Trajectory of Cancer-Related Fatigue
Aware of the gaps identified in the literature review, the author collaborated with the National Cancer Institute Radiation Oncology Branch at the NIH to develop a natural history study to describe the trajectory of fatigue reported by men with nonmetastatic prostate cancer treated with external beam radiation therapy (EBRT) (NCT00852111). This clinical population was observed to have no fatigue prior to treatment, develop fatigue during EBRT, and have complete resolution of their fatigue symptoms after completing their treatment (Miaskowski et al., 2008) . Therefore, the primary objective of this natural history study was to describe the fatigue and its cluster of symptoms prior to the start of their EBRT, then at midpoint, at completion of their treatment, and at 1 month, 3 months, 6 months, and 1 year after completing EBRT. Patients were treated daily, five times a week, for 38 to 44 days, depending on the stage of their prostate cancer. With each study visit, patients were asked to respond to several questionnaires that asked about their fatigue, sleep, overall well-being, catastrophizing, and depression. Blood was also drawn at each study visit to explore biomarkers of fatigue and to assess anemia. In collaboration with the NIH Clinical Center Rehabilitation Medicine Department, objective measures were added to measure physical activity and sleep using actigraphy, cognitive function using a computerized assessment of mild cognitive impairment (CAMCI ® ), and skeletal muscle strength using a hand grip dynamometer.
Application of the NIH SSM
Characterizing the fatigue phenotype. To determine the fatigue phenotype that can best inform the biological underpinnings of fatigue, we explored several published phenotyping approaches that have clinical meaning and can also provide the broadest physiologically relevant pathways to functionally pursue. We observed that three approaches to characterize the fatigue phenotype can provide both clinical meaning and suggest physiologically relevant functional pathways. Using the same set of patients, we observed that the 43-point cutoff of the Functional Assessment of Cancer TherapyFatigue (FACT-F) score generated the largest number of differentially expressed genes, which suggests that it can best capture the fatigue experience that is correlated with differences in gene expression. The 3-point change in FACT-F score was the best approach to isolate chronic fatigue, and the 50 T-score cutoff using the Patient Reported Outcome Measurement Information System-fatigue subscale (PROMIS-F) was the most sensitive approach to detect subtle changes in fatigue (Feng, Dickinson, Kline, & Saligan, 2016) .
Our natural history study provided the opportunity to investigate the development and persistence of fatigue related to EBRT. Fatigue scores of all study participants worsened during EBRT, which was primarily influenced by a drop in their hemoglobin levels (Feng et al., 2015) . At 1 year after completing EBRT, however, 37% of patients continued to experience clinically meaningful fatigue. Interestingly, this fatigue experience was not associated with hemoglobin levels, but was clustered with other symptoms like urinary symptoms, sleep disturbance, perceived cognitive impairment, and global pain (Feng, Suy, Collins, & Saligan, 2017) . This observation inspired us to investigate the biological underpinnings to explain the persistence of fatigue and its symptom cluster after completion of EBRT in a cohort of patients. Hence, we used the minimum important difference in FACT-F score, which is a >3-point change between two study time points, as previously reported (Cella, Eton, Lai, Peterman, & Merkel, 2002) . This approach was particularly useful in isolating persistent fatigue following EBRT (Feng et al., 2016) . Using this >3-point change approach, we observed that prior to EBRT, the fatigue symptoms of all our study participants were similar to those of the U.S. general population (Cella et al., 2002) .
Biomarker investigations. Two independent,
exploratory experiments were initially conducted from samples collected from study participants to explain the biology of chronic fatigue related to EBRT, using the >3-point change fatigue phenotyping approach. The first experiment was the whole genome microarray using whole blood RNA conducted in the NINR laboratory, and the other was a 48-panel Bio-Plex pro-inflammatory cytokine analysis using serum samples conducted in collaboration with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Translational Immunology Laboratory at the NIH. After false discovery rate correction, the pro-inflammatory cytokine panel revealed high concentrations of tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) in the chronic fatigue cohort (patients with persistent fatigue 1 year following EBRT) compared to the nonfatigued patients. Interestingly, the decoy receptor of TRAIL was also upregulated in the chronic fatigue group in the microarray results, suggesting that a persisting inflammatory process may be triggering the chronic fatigue experienced by men 1 year post-EBRT (Feng et al., 2017) .
Biomarker validation.
First, an independent validation study was conducted in collaboration with the MedStar Georgetown University Hospital, Department of Radiation Oncology, through a materials transfer agreement. Using a cohort of men with the same diagnosis and treatment regimen, our collaborators administered the same questionnaires and collected serum up to 2 years following EBRT. At that time point, although fatigue scores of patients were not correlated with urinary symptoms, they were still associated with TRAIL serum levels (Feng et al., 2017) , suggesting that TRAIL may be a specific biomarker of fatigue related to EBRT, independent of other symptoms (e.g., urinary dysfunction).
Second, to further investigate the role of TRAIL in the perceived cognitive impairment reported by our patients with chronic fatigue, we conducted an in vitro experiment to determine the toxicity of TRAIL in various cell types. We compared the effects of TRAIL on cell viability in neuronal, microglial, and myoblast cell lines. We observed that within 24 hr, TRAIL induced neuronal cell death at 5 μg/mL (p = .006) and 10 μg/mL (p = .0001). In contrast, TRAIL did not affect the cell viability of microglial or myoblast cells. Our in vitro findings suggest that neurons are particularly vulnerable to TRAIL, which may explain the significantly worse cognitive scores of our patients with chronic fatigue 1 year following EBRT (Feng et al., 2017) . To further the functional relevance of our findings, we developed a peripheral irradiationinduced fatigue mouse model in collaboration with the National Institute of Heart, Lung, and Blood Institute, Murine Phenotyping Core at the NIH (Wolff, Renner, Springer, & Saligan, 2017) . This model allowed us to further phenotype the fatigue behavior and to understand the interplay of central and peripheral mechanisms, such as the central and peripheral roles of TRAIL in the persistence of fatigue following irradiation.
Third, data generated from the whole genome microarray experiment allowed us to optimize biomarker discovery by identifying patients at risk for developing chronic fatigue 1 year following EBRT through a predictive algorithm put together by collaborators with bioinformatics and thermodynamics expertise from the Harvard University Biomedical Cybernetics Laboratory and University of Oviedo, Spain, respectively (Saligan, Fernandez-Martinez, deAndres-Galiana, & Sonis, 2014 ). The predictive model revealed that genes encoding glutamate receptors highly predicted which patients were at risk for developing chronic fatigue following radiation therapy (Feng et al., 2018) .
Understanding the role of glutamate receptors in fatigue development required a multiprong approach. First, we validated the top predictive gene (metabotropic glutamate receptor 5 [mGluR5], predictive accuracy = 85%) through TaqMan-based real-time quantitative polymerase chain reaction, where we found that mGluR5 expression can only be detected in the chronic fatigue cohort both before EBRT and 1 year after completing the treatment. The second approach was doing in vitro imaging to describe if mGluR5 activation triggers inflammation. Using confocal microscopy from our collaboration with the NIAMS Light Imaging Section at the NIH, we observed clustering of mGluR5 cultured T lymphocytes postirradiation, suggesting mGluR5 activation. Further, separate experiments pretreating T lymphocytes with mGluR5 antagonist and agonist revealed interesting results. T lymphocytes pretreated with mGluR5 antagonist showed similar morphology postirradiation as non-irradiated T lymphocytes, while mGluR5 agonist-pretreated T lymphocytes enhanced mGluR5 activation postirradiation. In addition, mGluR5 agonist-pretreated T lymphocytes triggered increased concentration of a pro-inflammatory chemokine, regulated on activation, normal T cell expressed and secreted (RANTES) postirradiation (Feng et al., 2018) , suggesting that stress-related activation of the glutamatergic pathway, such as daily doses of irradiation, may trigger the release of pro-inflammatory cytokines.
Fourth, having an interesting biomarker to pursue, we further validated the role of glutamate receptor in chronic fatigue related to radiation therapy. We collaborated with expert clinicians from the National Institute of Mental Health (NIMH) at the NIH who have been using a glutamate receptor antagonist to rapidly treat depression (Zarate et al., 2006) . We conducted a secondary analysis of the data collected from the NIMH clinical trial to determine if the same glutamate receptor antagonist had antifatigue effects. We observed that a single, nonanesthetic dose (0.5 mg/ kg) of ketamine, the glutamate receptor antagonist used, had rapid antifatigue effects, which was experienced 40 min after intravenous infusion and lasted for 2 days (Saligan, Luckenbaugh, Slonena, MachadoVieira, & Zarate, 2016) .
With this promising result from our secondary analysis of the NIMH data, we started a proof-of-concept clinical trial to validate the role of glutamate receptor in patients reporting chronic fatigue following radiation therapy (NCT02317341). We wanted to determine the rapid antifatigue effects of a single, subanesthetic intravenous dose of ketamine in patients who completed radiation therapy for cancer. We hypothesized that inhibiting glutamate receptors could increase postsynaptic glutamate concentration, a major excitatory neurotransmitter, reducing chronic fatigue symptoms of study participants. Initial responses from study participants who completed the clinical trial were encouraging. One participant shared this experience after completing the ketamine infusion:
Normally in the afternoon, I am so tired that I can barely think, and doing my I.T. job is difficult, but that day, I was marching up and down the stairwell during breaks, to release my energy. The energy boost faded in subsequent days.
Another participant mentioned, I didn't expect this effect, and I can't explain it. I know ketamine is used to treat depression, and there is a large correlation between depression and fatigue. I didn't think I was depressed. Whatever the mechanism, I am pleased with the result.
In addition, some patients who received the ketamine infusion reported relief of other symptoms clustered with fatigue, like general bodily pain. We are currently expanding this proof-of-concept clinical trial to determine the antifatigue effects of the glutamate receptor antagonist in fatigue related to chronic illness (e.g., chronic fatigue syndrome, fibromyalgia). Evidence suggests that fatigue in diverse medical conditions is driven by shared biological mechanisms (e.g., inflammation, mitochondrial dysfunction); hence, identifying a potential antifatigue agent in one medical condition may be valuable to understand the shared fatigue mechanism across clinical populations and can assist in optimizing an antifatigue therapy for all fatiguing conditions. Using the NIH SSM, our current clinical and laboratory research activities are expanding by validating the generalizability of these initial fatigue biomarkers using a larger sample size and more diverse clinical populations. For example, we are exploring whether increased TRAIL plasma concentrations are particularly responsible in exercise intolerance reported by chronic fatigue patients. We hypothesize that exercise intolerance reported by chronic fatigue patients is related to the systemic toxic effects of TRAIL on neurons. We are also interested to explore whether specific glutamate receptor gene mutations can trigger pro-inflammatory tone in select patients, placing these patients at risk for developing chronic fatigue after cancer therapy. We hypothesize that select individuals carrying specific gene mutations of glutamate receptors can cause inflammation triggered by repeated stress, placing these individuals at risk for developing clusters of symptoms, including chronic fatigue. The NIH SSM clearly provided an investigative sequence to follow in the conduct of symptom science research to allow the constant generation of discovery that is clinically relevant.
Conclusions
The symptom science focus of the NINR intramural research program, which aims to promote translational nursing research as guided by the NIH SSM, provides a unique content expertise in the general scientific community. The NINR intramural program's strength in building a multidisciplinary network of research collaborations led by nurse scientists, its access to NIH resources, and its strength in conducting sequential investigations using innovative approaches (e.g., in vitro cell models, animal models, clinical trials) to probe deeper into the biology of symptoms, provide an opportunity for nursing science to lead in discoveries of targeted therapeutics and risk reduction strategies.
Training
The systematic sequential approach of our research activities, as guided by the NIH SSM, has been uniquely useful in developing training curricula for our fellows and students. Our trainees have unique opportunities to have a focused training goal to achieve within a specific time duration or to be immersed in the full array of research activities the NINR intramural research program offers. These opportunities are particularly valuable to accommodate a wide range of trainees. Examples include a nurse faculty member who has a foundation training grant and seeks to learn some strategies to phenotype symptoms, a postdoctoral fellow who wants to build laboratory skills and find functional relevance of initial clinical findings through in vitro techniques or animal behavior experiments, and a doctoral student who conducts a secondary analysis of biobehavioral data or tests a hypothesis using translational approaches. In addition, this sequential approach of our research activities allows the trainee to better define the training outcomes and deliverables. Hence, the inclusion of the NINR intramural research program in the NNRR program provided an opportunity to describe a research exemplar highlighting the ground-breaking strategies being used to generate hypotheses, validate findings, and quickly build evidence to advance symptom science.
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